Cellectis to present updated clinical and preclinical data at hematology conference

Cellectis S.A., a gene-editing company, announced it will present updated preliminary clinical data from its BALLI-01 study and initial preclinical data for its TALGlobin01 program at the 63rd American Society of Hematology (ASH) Annual Meeting. The conference takes place from December 11-14, 2021.

The BALLI-01 study is evaluating UCART22, an allogeneic CAR-T cell therapy, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The presentation will include preliminary data from the Phase I, dose-escalation trial, suggesting that the addition of alemtuzumab to fludarabine and cyclophosphamide lymphodepletion was well-tolerated and promoted CAR-T cell expansion.

The TALGlobin01 program targets sickle cell disease (SCD) using gene therapy. The preclinical data to be presented are the first to demonstrate the potential of Cellectis' TALEN® gene editing technology to correct the mutated beta-globin gene in hematopoietic stem and progenitor cells derived from patients with the disease. The data reportedly show high levels of hemoglobin A expression and reversal of the sickling phenotype.

Cellectis is advancing its pipeline of allogeneic CAR-T cell therapies and gene therapies for genetic diseases. The company stated that the encouraging data from the BALLI-01 study support continued enrollment. Further data from both programs will be presented at the ASH meeting.